CareCapital Acquires Purgo Biologics to Advance Global Regenerative Biomaterials Leadership
On October 14, 2020, in Seoul, South Korea, Shuangbai Investment, one of the global leaders in the oral care industry, announced the signing of an agreement to acquire Purgo Biologics, a South Korea-headquartered global enterprise specializing in dental bone regeneration, thereby initiating a strategic collaboration oriented toward future biomedicine. Shuangbai will continue to invest resources in scientific research and biopharmaceutical manufacturing, actively promoting Purgo’s development into a globally leading biomaterials company. This initiative aims to provide high-quality products and professional services to a broader customer base and drive the growth of the bio-regenerative materials market.
PineBridge Capital and Purgo jointly chart a long-term development blueprint, with both parties collaborating to develop more safe and reliable bioregenerative products while continuing to leverage the outstanding clinical efficacy of Purgo’s products.1、2, leveraging Songbo’s global partnership network and Purgo’s successful experience in the South Korean market, is committed to becoming a leader in the field of bioregeneration in key markets such as China, Europe, and the United States.
Founded in 1999, Purgo specializes in the research and development, production, and sales of safe biomaterials for dental soft tissue and bone regeneration. Through various clinical studies and collaborative research with government bodies, clinicians, and educational institutions, Purgo has developed a comprehensive portfolio of dental soft tissue and bone regeneration biomaterials that meet international quality standards, including THE Graft.TMBone Powder, OpernTex®️Non-absorbable collagen membrane, Biotex®️PTFE Sutures and BioCover®️Resorbable collagen membranes, among others. Its bone regeneration solutions have been registered in 41 countries and regions, including the European Union, the United States, and Japan. Globally, these solutions are widely favored by dentists for both scientific research and clinical applications. As a technical expert in the field of bone regeneration, founder Mr. Kang Ho Chang has dedicated over a decade to the research and development of dental bone tissue regeneration products and has published numerous articles on xenogeneic bone graft materials.
As a global leader in building the dental industry, Songbo Investment is committed to addressing pain points in dental industry and disciplinary development through an integrated approach of investment and operation, thereby driving industrial growth. Medical solutions based on advanced material technologies have always been one of the core areas of Songbo’s R&D investment, aiming to improve healthcare quality and effectively reduce medical costs through innovative technologies and products, so that technological advancements can benefit a broader population.
Mr. Kang Ho Chang, Founder of Purgo, will continue to serve as CEO. He stated, “Dental Capital focuses on building medical disciplines and industries, acting as a steadfast and powerful supporter of long-term corporate development. We are delighted to have found a shareholder partner who shares our development philosophy and possesses abundant industry resources, enabling us to work together for mutual success. I was deeply impressed by Dental Capital’s profound understanding of bioregenerative technology and its long-term development strategy, which completely changed my perspective on external investors. This convinces me that only by partnering with Dental Capital can Purgo truly reach new heights and realize my vision.”
Mr. Yoon Chang-bae, Head of South Korea Operations at Shuangbai Investment, expressed strong confidence in the company’s prospects. He stated, “Purgo is South Korea’s premier dental bone regeneration company, boasting leading-edge technology and widespread recognition within the Korean dental community. On one hand, Shuangbai will assist Purgo in better expanding into the Chinese, European, and American markets, fostering extensive and in-depth collaborations with numerous globally renowned academic institutions and enterprises. On the other hand, Shuangbai will also help Purgo further enhance its current technology platform, enabling its expansion into the broader field of regenerative medicine.”
To realize the development blueprint for a global market layout, Songbo Investment and Purgo are well aware of the importance of deeply cultivating the Chinese market.
Purgo offers a comprehensive portfolio of dental bone regeneration products, including its flagship brand Bio-Oss® THE Graft.TMBone powder, with its unique biological scaffold structure, high porosity, excellent biocompatibility, and hydrophilicity3、4Its ease of use has been widely recognized by dentists in many countries, making it the best-selling dental bone graft material in South Korea.
Many customers in China’s dental bone regeneration market lack access to suitable products and training. Following its acquisition of Purgo, Songbo Investment Holdings will fully promote the clinical application of Purgo’s bone regeneration products in China, thereby expanding the range of choices available to Chinese dentists.
Currently, Bio-Oss THE GraftTMThe bone graft material has obtained the Import Medical Device Registration Certificate in China. Moving forward, Purgo will fully leverage the industrial network advantages of Songbo Investment to engage in extensive collaborations with enterprises both domestically and internationally. Songbo will establish a specialized clinical research team to conduct clinical research projects in partnership with renowned dental institutions at home and abroad. By continuously investigating and evaluating the clinical efficacy of its products across various indications and accumulating clinical data, the company aims to further enhance product performance.
Songbai Investment Partners and Purgo Join Forces to Launch a New Phase of Global Expansion. This initiative will facilitate the exchange and widespread adoption of advanced bio-regenerative material technologies and proven best practices across countries and regional markets, thereby driving the robust growth of the bio-regenerative materials industry.
Songbo Investment is committed to becoming a builder of the dental discipline and industry. Through controlling stakes and equity investments, Songbo extensively participates in the development of various sectors within the dental industry across Asia, North America, and Europe. Along the upstream, midstream, and downstream segments of the dental industry chain, Songbo Investment holds controlling interests in leading enterprises such as Angelalign, China’s leading clear aligner brand; Songbai Dental, a national dental distribution group; and large-scale specialized dental hospitals in South China, including Huizhou Stomatological Hospital and Heyuan Hengxin Stomatological Hospital. Its investment and business collaboration network also includes numerous leading companies such as product manufacturers Carestream Dental, Germany’s BEGO implants, and South Korea’s Medit intraoral scanners; dental healthcare brands Henglun Dental, Tongbu Dental, and More Dental; and the dental distributor Huaguang Dental Group. Recently, Songbo Investment announced its investment in Upcera, China’s largest restorative materials company, along with a series of strategic collaborations.
References:
1、LEE,Jung Seok; CHA,Jae Kook; KIM,Chang Sung. Alveolar ridge regeneration of damaged extraction sockets using deproteinized porcine versus bovine bone minerals: A randomized clinical trial. Clinical implant dentistry and related research ,2018,20.5:729 -737.
2、 LEE,Jung Seok; et al。Randomized clinical trial of maxillary sinus grafting using deproteinized porcine and bovine bone mineral. Clinical implant dentistry and related research ,2017,19.1:140-150.
3、 FIGUEIREDO,M.,et al. Effect of the calcination temperature on the composition and microstructure of hydroxyapatite derived from human and animal bone. Ceramics international ,2010,36.8:2383-2393.
4、Lee JH, Yi GS ,Lee JW, Kim DJ. Physicochemical characterization of porcine bone-derived grafting material and comparison with bovine xenografts for dental applications. J Periodontal Implant Sci.2017 Dec;47(6):388-401.